Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

Abstract: Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33.

Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2?receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.

Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.

Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.

Abstract: Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33.

Abstract: Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-A?R?nYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4?)-biphenylalanine or D-(4,4?)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.

Abstract: Peptides that modulate the glucagon response in a mammal are provided. The peptides comprise an amino acid sequence of between about 5 and about 10 amino acids in length that corresponds to the sequence of an extracellular membrane insertion region of a mammalian glucagon receptor, wherein at least one amino acid of the peptide has a D-configuration. Methods of preparing the peptides and the use of the peptides in the amelioration, treatment and/or prevention of glucagon-mediated conditions and diseases such as hyperglycemia, diabetes and obesity are also provided.

Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.

Abstract: The present invention relates to a peptide of Formula I, or a pharmaceutically acceptable salt thereof: X—P??Formula I wherein: P is a DPPIV peptide metabolite of regulatory peptides obtained by cleavage of the two N-terminal amino acids; and X is defined by Formula II: wherein: A is selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C1-C10 heteroalkylene, C2-C10 heteroalkenylene, C2-C10 heteroalkynylene and phenyl; and B is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl and C3-C7 cycloalkyl.

Abstract: Methods of modulating the function of G-protein coupled receptors (GPCRs) using peptide antagonists of the GPCR are provided. The peptide antagonists are derived from the sequence of a juxtamembrane extracellular structural element of the target GPCR and selectively modulate the function of the receptor from which they are derived. The GPCR peptide antagonists include peptides comprising naturally occurring amino acids as well as peptide analogues, peptide derivatives, peptidomimetics and peptide variants. Methods of selecting the peptide antagonists are also provided. The peptides have therapeutic application in the treatment, amelioration or prophylaxis of diseases or conditions associated with changes in GPCR activity.

Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: